Effects of Dual-Release Hydrocortisone on Bone Metabolism in Primary and Secondary Adrenal Insufficiency: A 6-Year Study.

Valeria HasenmajerDavide FerrariDario De AlcubierreValentina SadaGiulia PulianiIlaria BonaventuraMarianna MinnettiAlessandra TomaselliRiccardo PofiEmilia SbardellaAlessia CozzolinoDaniele Gianfrilli Andrea M Isidori

Published in: Journal of the Endocrine Society (2023)

After 6 years of chronic DR-HC replacement, BMD and bone markers remained stable. TBS decline is more likely due to an age-related derangement of bone microarchitecture rather than a glucocorticoid effect. Our data confirm the safety of DR-HC replacement on bone health in both PAI and SAI patients.

Keyphrases

bone mineral density
soft tissue
bone loss
end stage renal disease
bone regeneration
healthcare
public health
chronic kidney disease
ejection fraction
newly diagnosed
postmenopausal women
prognostic factors
machine learning
body composition
electronic health record
social media